Overview

Inflammation and Coronary Endothelial Function

Status:
Completed

Trial end date:
2020-09-01

Target enrollment:

Participant gender:

Summary

The investigators are studying whether anti-inflammatory agents can improve abnormal coronary artery function in patients with coronary artery disease (CAD) and abnormal coronary artery endothelial function.

Phase:

Phase 2

Details

Lead Sponsor:

Johns Hopkins University

Collaborator:

National Heart, Lung, and Blood Institute (NHLBI)

Treatments:

Anti-Inflammatory Agents
Colchicine
Methotrexate